Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAYNASDAQ:NVNONASDAQ:PAVMNASDAQ:UTRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsway$13.22+0.9%$10.23$5.67▼$13.25$249.79M1.3267,611 shs33,273 shsNVNOenVVeno Medical$4.07-2.4%$3.65$2.03▼$6.48$71.37M0.92111,319 shs107,831 shsPAVMPAVmed$0.60-2.9%$0.67$0.55▼$1.90$10.26M1.06134,986 shs123,402 shsUTRSMinerva Surgical$0.00$0.00▼$0.00$1K3.67259 shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsway0.00%+21.17%+26.75%+42.15%+112.20%NVNOenVVeno Medical0.00%+0.49%+8.53%+48.00%-20.97%PAVMPAVmed0.00%+3.45%-2.52%-20.00%-19.14%UTRSMinerva Surgical0.00%0.00%0.00%0.00%-99.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsway1.4251 of 5 stars1.53.00.00.02.10.81.9NVNOenVVeno Medical1.2269 of 5 stars0.04.00.00.03.30.80.6PAVMPAVmed4.5515 of 5 stars3.55.00.04.31.60.01.9UTRSMinerva SurgicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsway 3.00Buy$14.257.79% UpsideNVNOenVVeno Medical 0.00N/AN/AN/APAVMPAVmed 3.00Buy$19.003,066.67% UpsideUTRSMinerva Surgical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BWAY, NVNO, PAVM, and UTRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025BWAYBrainswayHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/6/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.50 ➝ $19.004/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.50(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsway$41.02M6.09$0.25 per share53.02$3.31 per share3.99NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/APAVMPAVmed$2.99M3.43N/AN/A($0.92) per share-0.65UTRSMinerva Surgical$51.69M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsway$2.92M$0.2066.1082.63N/A9.01%7.35%4.72%8/5/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.18N/AN/AN/AN/A-51.32%-48.23%7/30/2025 (Estimated)PAVMPAVmed$39.79M$0.710.85N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)UTRSMinerva Surgical-$34.11MN/A0.00N/AN/AN/AN/AN/AN/ALatest BWAY, NVNO, PAVM, and UTRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BWAYBrainsway$0.02$0.04+$0.02$0.04$11.45 million$11.54 million4/30/2025Q1 2025NVNOenVVeno MedicalN/A-$0.22N/A-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainswayN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/AUTRSMinerva SurgicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainswayN/A5.034.75NVNOenVVeno MedicalN/A23.7723.77PAVMPAVmedN/A0.370.37UTRSMinerva SurgicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsway30.11%NVNOenVVeno Medical34.71%PAVMPAVmed19.93%UTRSMinerva SurgicalN/AInsider OwnershipCompanyInsider OwnershipBWAYBrainsway19.00%NVNOenVVeno Medical16.00%PAVMPAVmed7.30%UTRSMinerva Surgical8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsway12018.90 million15.31 millionNot OptionableNVNOenVVeno Medical1917.54 million14.73 millionOptionablePAVMPAVmed9017.09 million15.85 millionOptionableUTRSMinerva Surgical1608.88 million8.12 millionNot OptionableBWAY, NVNO, PAVM, and UTRS HeadlinesRecent News About These CompaniesMinerva Surgical Inc.January 10, 2024 | thestreet.comWhy Is Minerva Surgical (UTRS) Stock Down 50% Today?December 18, 2023 | markets.businessinsider.comMinerva Surgical Inc UTRSDecember 17, 2023 | morningstar.comMMinerva Surgical, Inc.: Minerva Surgical Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finanznachrichten.deMinerva Surgical GAAP EPS of -$0.81 misses by $0.27, revenue of $12M misses by $1.93MNovember 14, 2023 | msn.comMinerva Surgical Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | finance.yahoo.comAccelmed Files Transaction Statement on Schedule 13E-3 with Securities and Exchange CommissionSeptember 29, 2023 | finance.yahoo.comMinerva Surgical Inc (UTRS) Becoming More Attractive for InvestorsSeptember 27, 2023 | knoxdaily.comKUTRS Shares Experience Surge in ValueAugust 25, 2023 | knoxdaily.comKMinerva Surgical Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comMinerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue EstimatesAugust 3, 2023 | finance.yahoo.comInvestors in Minerva Surgical (NASDAQ:UTRS) from a year ago are still down 86%, even after 51% gain this past weekMay 25, 2023 | finance.yahoo.comPatent Grant Sends Healthcare Shares Soaring PremarketMay 24, 2023 | theglobeandmail.comWhy Minerva Surgical Shares Are Taking Off WednesdayMay 24, 2023 | msn.comWhy Is Minerva Surgical (UTRS) Stock Up 229% Today?May 24, 2023 | msn.comQ1 2023 Minerva Surgical Inc Earnings CallMay 3, 2023 | finance.yahoo.comMinerva Surgical Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comModified Minerva orthosis proven helpful in pediatric patients following airway surgeryMay 2, 2023 | medicalxpress.comMMinerva Surgical to Announce First Quarter 2023 Financial ResultsApril 18, 2023 | finance.yahoo.comMinerva Surgical, Inc. (NASDAQ:UTRS) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBWAY, NVNO, PAVM, and UTRS Company DescriptionsBrainsway NASDAQ:BWAY$13.22 +0.12 (+0.92%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$13.05 -0.17 (-1.29%) As of 06/27/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.enVVeno Medical NASDAQ:NVNO$4.07 -0.10 (-2.40%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$4.12 +0.05 (+1.35%) As of 06/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. PAVmed NASDAQ:PAVM$0.60 -0.02 (-2.90%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.61 +0.01 (+1.50%) As of 06/27/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Minerva Surgical NASDAQ:UTRSMinerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
